Return to homepagePandemic Pact

Harnessing the inherent immunosuppressive properties of allogenic mesenchymal stem cells (MSCs)

  • Funded by UK Research and Innovation (UKRI)
  • Total publications:0 publications

Grant number: C19-IUC-281

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    UK Research and Innovation (UKRI)

  • Principal Investigator

    Ingo Ringshausen

  • Research Location

    United Kingdom

  • Lead Research Institution

    Wellcome - Medical Research Council Cambridge Stem Cell Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Aiming to harness the inherent immunosuppressive properties of allogenic mesenchymal stem cells (MSCs) which can be used to treat severe inflammation in the lungs. The team are seeking to identify therapies using small-molecules that could address patients experiencing severe Covid-19 inflammation in their lungs without the need for cell transplantation.